A plasma N-acetyl amino acid panel for type 2 diabetes discrimination built by targeted LC–MS/MS: A case–control study - Takeaways - MDSpire

A plasma N-acetyl amino acid panel for type 2 diabetes discrimination built by targeted LC–MS/MS: A case–control study

  • By

  • Shusi Ding

  • Zhanxiong Xie

  • Daqiu Chen

  • Xiaomai Huang

  • Qiutong Wu

  • Lemin Zheng

  • Shanghua Xu

  • Shunxiang Luo

  • June 3, 2026

  • 0 min

Share

  • 1

    The study developed a targeted LC–MS/MS assay to quantify 19 plasma N-acetyl amino acids (NAcAAs) in individuals with type 2 diabetes (T2D) and controls.

  • 2

    Plasma NAcAA profiles showed significant differences between T2D patients and non-diabetic controls, with specific metabolites increasing or decreasing.

  • 3

    N-acetyltryptophan was positively associated with T2D, while N-acetylproline and N-acetyllysine showed inverse associations in logistic regression models.

  • 4

    An 8-metabolite panel derived from NAcAAs demonstrated excellent discriminatory performance for T2D, with an AUC of 0.963.

  • 5

    The findings suggest that NAcAAs may serve as potential biomarkers for metabolic risk characterization in type 2 diabetes.

Original Source(s)

A plasma N-acetyl amino acid panel for type 2 diabetes discrimination built by targeted LC–MS/MS: A case–control study

  • by Shusi Ding, Zhanxiong Xie, Daqiu Chen, Xiaomai Huang, Qiutong Wu, Lemin Zheng, Shanghua Xu, Shunxiang Luo

  • June 3, 2026

Related Content

Neo or Not Neo? Widefield OCT-A Reveals Hidden Neovascularization

Utilizing OCT and OCT-A technologies revealed critical insights into a patient’s complex retinopathy, as highlighted by Dr. Julie Rodman.

AACE 2026: Will AI replace endocrinologists?

The same technology drawing patients away from clinic may also improve the patient-physician relationship.

Detection of Referable Diabetic Retinopathy using Machine Learning on Routine Clinical Data